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Abstract 
An increasing number of commonly prescribed drugs are known to interfere with mitochondrial function, 
causing cellular toxicity, but the underlying mechanisms are largely unknown. Although often not 
considered, mitochondrial transport proteins form a significant class of potential mitochondrial 
off-targets. So far, most drug interactions have been reported for the mitochondrial ADP/ATP carrier 
(AAC), which exchanges cytosolic ADP for mitochondrial ATP. Here, we show inhibition of cellular 
respiratory capacity by only a subset of the 18 published AAC inhibitors, which questions whether all 
compound do indeed inhibit such a central metabolic process. This could be explained by the lack of a 
simple, direct model system to evaluate and compare drug-induced AAC inhibition.  
Methods: For its development, we have expressed and purified human AAC1 (hAAC1) and applied two 
approaches. In the first, thermostability shift assays were carried out to investigate the binding of these 
compounds to human AAC1. In the second, the effect of these compounds on transport was assessed in 
proteoliposomes with reconstituted human AAC1, enabling characterization of their inhibition kinetics.  
Results: Of the proposed inhibitors, chebulinic acid, CD-437 and suramin are the most potent with 
IC50-values in the low micromolar range, whereas another six are effective at a concentration of 100 µM. 
Remarkably, half of all previously published AAC inhibitors do not show significant inhibition in our 
assays, indicating that they are false positives. Finally, we show that inhibitor strength correlates with a 
negatively charged surface area of the inhibitor, matching the positively charged surface of the substrate 
binding site.  
Conclusion: Consequently, we have provided a straightforward model system to investigate AAC 
inhibition and have gained new insights into the chemical compound features important for inhibition. 
Better evaluation methods of drug-induced inhibition of mitochondrial transport proteins will contribute 
to the development of drugs with an enhanced safety profile. 
Key words: drug-induced mitochondrial dysfunction; mitochondrial transport proteins; adenine nucleotide 
translocase; thermostability shift; transport inhibition kinetics. 
Introduction 
Mitochondria produce the majority of cellular 
ATP, and are a central hub for many metabolic 
pathways [1]. The advent of molecular medicine has 
implicated mitochondria as major regulators of cell 
death [2] and in the initiation and propagation of 
innate immune responses and inflammatory reactions 
[3, 4]. Consequently, their dysfunction is associated 
with many inherited and common disorders, 
including neurodegenerative, developmental and 









and cardiovascular disorders [1, 5-9]. 
Moreover, a steadily increasing number of 
commonly prescribed drugs are known to interfere 
with mitochondrial function, including cholesterol- 
lowering and anti-diabetic drugs, antibiotics, 
chemotherapeutics and immunosuppressants [10-14]. 
The relevance of drug-induced mitochondrial 
dysfunction in adverse drug effects is exemplified by 
the observation that it associates with approximately 
50% of all FDA black box warnings [15]. In addition, a 
screen of 676 unique compounds demonstrated that 
73% negatively affected mitochondrial function [16]. 
Although drugs can potentially interfere with 
the function of all ~1200 mitochondrial proteins [17], 
mitochondrial drug off-target mechanisms are 
generally categorized as inhibition of oxidative 
phosphorylation, respiratory uncoupling, 
permeability transition pore opening, suppression of 
fatty acid β-oxidation, and affected mitochondrial 
DNA replication, transcription or translation [18]. 
Although often not considered, mitochondrial 
transport proteins form another significant class of 
potential mitochondrial off-targets, as they account 
for more than five percent of the mitochondrial 
proteome. Moreover, they have a pivotal role in 
mitochondrial metabolism, as they facilitate the 
transport of metabolites, inorganic ions and cofactors 
across the largely impermeable mitochondrial inner 
membrane, linking the metabolic pathways of the 
mitochondrial matrix with those in the cytosol [1, 19, 
20]. This central role in cellular metabolism is 
emphasized by the association of various inborn 
mitochondrial diseases with mitochondrial transport 
protein deficiencies [19]. 
Most of these transporters belong to the 
mitochondrial carrier family, consisting of 53 
members that enable import and efflux of a wide 
variety of metabolites [1, 19, 20]. Other types of 
transport proteins that are embedded in the 
mitochondrial inner membrane include ATP-binding 
cassette (ABC) transporters [21], various ion-channels, 
sideroflexins [22, 23] and the mitochondrial pyruvate 
carrier [24, 25]. Expression patterns vary greatly 
between different carriers, ranging from ubiquitous to 
organ-specific expression [26-28]. Although 
mitochondrial carriers are involved in the import and 
export of a large variety of chemically distinct cellular 
metabolites, they are likely to have a similar 
mechanism of transport, which has recently been 
elucidated for the mitochondrial ADP/ATP carrier 
(AAC) [1, 29].  
The AAC is the canonical member of the SLC25 
mitochondrial carrier family, importing ADP from the 
cytosol in exchange for mitochondrial ATP [29-32]. 
Consequently, this carrier mediates an essential step 
in eukaryotic oxidative phosphorylation [29-32]. The 
carrier is composed of three homologous domains, 
each of which contains two transmembrane 
alpha-helices linked by a hydrophilic loop with a 
small helix facing the matrix space; both the N- and 
C-terminal regions extend into the intermembrane 
space of mitochondria [33]. The transport mechanism 
requires the carrier to cycle between cytoplasmic- and 
matrix-open states, alternating the accessibility of the 
central substrate binding site to these compartments 
[29, 34]. There are four human AAC isoforms 
expressed from different genes (SLC25A4, SLC25A5, 
SLC25A6 and SLC25A31) [35]. The carriers cycle 
between a cytoplasmic-open and matrix-open state 
via an occluded state, which is closed on both the 
matrix and cytosolic side [29-31, 34]. The differences 
in tissue-specific transcription of these isoforms are 
thought to be associated with the distinct energy 
requirements of various cell types in different states of 
cellular differentiation [35-37]. 
The central role of this carrier in energy 
metabolism makes it a potentially important off-target 
underlying drug-induced mitochondrial dysfunction. 
The first report linking AAC inhibition to 
mitochondrial dysfunction dates to the 1960s, 
describing the toxic effects of atractyligenin, a coffee 
bean extract and precursor of the most potent 
canonical AAC inhibitor carboxyatractyloside (CATR) 
[38]. Mitochondrial ADP-uptake inhibition by the 
diuretics ethacrynic acid and furosemide [39], 
illustrate the first cases of AAC inhibition by 
commonly used drugs. AAC inhibition has also been 
observed with various other commonly used drugs, 
including several non-steroid anti-inflammatory 
drugs (aspirin, diclofenac, indomethacin, and 
nimesulide), the anti-depressant sertraline, drugs 
used to treat psoriasis (anthralin and tretinoin), the 
antibiotic equisetin, and the antiretroviral drug 
zidovudine [40-47]. Toxicity of two potential 
anti-obesity drugs (ibipinabant and leelamine) was 
associated with AAC inhibition in preclinical drug 
development studies [48, 49]. More recently, AAC 
inhibition has been explored as an anti-cancer 
therapy, as isoform 2 has been associated with cancer 
cell metabolism [36]. This observation has initiated the 
exploration of novel AAC inhibitors, including 
CD-437, and two flavonoids (quercetin and apigenin) 
[49-54]. In this context, specific AAC2 inhibition was 
shown for chebulinic acid and suramin, the latter of 
which is a treatment for African sleeping sickness [55]. 
Moreover, inhibition of isoform 4 has recently been 
explored as a novel therapeutic strategy for male 
contraception, as this isoform is expressed in male 
reproductive tissues [56].  
Previously used methods to detect drug-induced 





AAC inhibition often involve complex whole cell- or 
mitochondria-based assays, or overexpression of 
human isoforms in the Gram-positive bacterium 
Lactococcus lactis [49] and in the yeast Saccharomyces 
cerevisiae [49, 55]. Alternatively, human AAC2 has 
been expressed in inclusion bodies, refolded and 
reconstituted into proteoliposomes, which were used 
to study the inhibitory effects of chebulinic acid and 
suramin [55]. The use of a wide range of 
methodologies, as well as indirect model systems, 
limits the direct comparison of the proposed 
inhibitors, but more importantly, any inhibitory 
effects may be due to indirect effects, mediated via 
other mitochondrial off-target mechanisms. The use of 
purified, detergent-solubilized human AAC could 
overcome this limitation, but the yield is low when 
isolated from human mitochondria [57]. Similar 
problems with protein yield have hampered the 
expression of human AAC isoforms in bacteria and 
yeast cells [58-60]. 
Here, we describe the expression in 
Saccharomyces cerevisiae, purification and functional 
reconstitution of functional human AAC1 (hAAC1), 
the main isoform present in heart and skeletal muscle 
[35, 37]. We use thermostability shift measurements of 
hAAC1 to investigate the binding of these 
compounds, demonstrating its advantages and 
limitations as a high-throughput screening method to 
identify potential adverse drug interactions with the 
carrier. Finally, the effect of these compounds on 
transport was assessed in proteoliposomes, enabling 
direct characterization of the inhibition kinetics. 
Materials and Methods 
Chemicals 
Equisetin, CD-435 and ibipinabant ((S)-SLV 319) 
were purchased from Cayman Chemical Company. 
Leelamine was purchased from Toronto Research 
Chemicals. All other chemicals were purchased from 
Merck, unless otherwise stated. 
Cell culture  
HeLa cells (American Type Culture Collection, 
CCL-2) were maintained at 37 °C in a humidified 
atmosphere of 5% (v/v) CO2 in Dulbecco’s Modified 
Eagle’s medium (DMEM) containing 25 mM 
D-glucose, GlutaMAXTM, 1 mM pyruvate (GibcoTM 
Life Technologies) supplemented with 10% (v/v) Fetal 
Bovine Serum (FBS, GibcoTM Life Technologies) and 
split to maintain cellular confluency below 90% in 75 
cm2 cell culture vessels (Corning).  
Cellular and mitochondrial oxygen 
consumption analysis 
Analysis of cellular and mitochondrial 
respiratory capacity was performed using the 
Seahorse XF96 extracellular flux analyzer (Agilent). 
HeLa cells were counted using a Countess automated 
cell counter (ThermoFisher Scientific), and seeded in 
96-well cell culture plates 24-h prior to the experiment 
at a 14,000 cells per well density. We used cells with 
passage numbers ranging between 14 and 18, to 
minimize the contribution passage-dependent 
metabolic changes. Culture medium was replaced one 
hour before initiation of the experiment by sodium 
bicarbonate free DMEM medium, pH 7.4, 
supplemented with 1 mM pyruvate, 25 mM 
D-glucose, 32 mM NaCl and 10 mM HEPES. Cells 
were allowed to reach a stable routine oxygen 
consumption, after which the compounds were added 
(final DMSO concentration 0.1% (v/v)). Subsequently, 
oxygen consumption was measured for 90 min, after 
which we continued using ‘cell mito stress test’ 
protocol as described previously [61]. To determine 
mitochondrial oxygen consumption rates, culture 
medium was removed and washed once with 
mitochondrial assay solution (MAS; pH 7.2, 70 mM 
sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM 
MgCl2, 2 mM HEPES, 1 mM EGTA, 0.2% (w/v) 
essentially fatty acid-free bovine serum albumin). 
Subsequently, cells were permeabilized 20 min prior 
to initiation of the experiment by the addition of MAS 
containing 10 µg ⋅ mL-1 digitonin, 10 mM glutamate, 
and 10 mM malate. Cells were allowed to reach stable 
non-stimulated respiration, after which the 
compounds were added (final DMSO concentration 
0.1% (v/v)). Subsequently, oxygen consumption was 
measured for 90 min, after which 4 mM ADP was 
added to determine maximal ADP-stimulated 
respiration. 1 µM rotenone (final DMSO concentration 
0.04% (v/v)) and 2.5 µM antimycin A (final DMSO 
concentration 0.04% (v/v)) were added simultaneously 
to obtain non-mitochondrial respiration, as described 
previously [62]. For both cellular and mitochondrial 
oxygen consumption, non-mitochondrial respiratory 
rates were subtracted from all respiratory rates. Next, 
all rates were normalized to the average of the first 
three data points (T0).  
Expression of human AAC in Saccharomyces 
cerevisiae 
Human ADP/ATP carrier isoform 1, 
codon-optimized for expression in Saccharomyces 
cerevisiae (GenScript), was truncated using PCR, 
resulting in a construct encoding residues 11-298 
(hAAC1Δ1-10). The AAC2 from Saccharomyces 
cerevisiae, encoding the full sequence was a generous 
gift from Dr. Jonathan Ruprecht [63]. The yeast AAC2, 
complete hAAC1, and hAAC1Δ1-10 constructs were 
engineered to contain an N-terminal tag composed of 





eight histidine residues and a Factor Xa protease 
cleavage site, and cloned into a pYES3/CT vector 
(Invitrogen) with a constitutively active promoter 
(pMIR) as described previously [34]. Sequence- 
verified plasmids were transformed into 
Saccharomyces cerevisiae strains WB.12 (MATa ade2-1 
trp1-1 ura3-1 can1-100 aac1::LEU2 aac2::HIS3) [64] and 
W303-1B (MATα leu2-3,112 trp1-1 can1-100 ura3-1 
ade2-1 his3-11,15) using the LIAc/SS carrier 
DNA/PEG method [65]. Transformants were selected 
on Sc-Trp + 2% (w/v) glucose plates. For large scale 
expression, a pre-culture of cells grown in Sc-Trp + 
2% (w/v) glucose was inoculated into 100 L of YEPG 
medium in an Applikon Pilot Plant 140 L bioreactor. 
Cells were grown at 30 °C for 24 h and harvested by 
centrifugation (4,000 g, 20 min, 4 °C). Crude 
mitochondria were prepared using a bead mill 
(Dyno-Mill Multilab, Willy A. Bachofen AG) by 
established methods [66]. 
Functional complementation of Saccharomyces 
cerevisiae AAC knockout strain 
The rescue of non-fermentative growth of WB.12 
by expression of ScAAC2, hAAC1, and hAAC1∆1-10 
was assessed on YPG media. Transformant cells from 
glycerol stocks were inoculated into 5 mL Sc-Trp + 2% 
(w/v) glucose and incubated overnight at 30 °C with 
aeration at 225 rpm. The cells were pelleted by 
centrifugation (3,000 g, 10 min, 4 °C), washed four 
times with sterile de-ionized water, resuspended in 1 
mL of water and the OD600 was adjusted to one. Serial 
dilutions were carried out (105 - 101) cells were spotted 
onto YPG plates, and incubated at 30 °C for 6 days. 
Preparation of lipid for protein purification 
Tetraoleoyl cardiolipin (18:1) powder was 
purchased from Avanti Polar Lipids (#840012C) and 
solubilized in 10% (w/v) dodecyl maltose neopentyl 
glycol (Anatrace) by vortexing for 4 h at room 
temperature to give 10 mg ⋅ mL-1 lipid in a 10% (w/v) 
detergent stock. The stocks were stored in liquid 
nitrogen. 
Purification of human AAC via nickel affinity 
chromatography 
Approximately one gram of isolated crude 
mitochondria was solubilized in 1% (w/v) dodecyl 
maltose neopentyl glycol, protease inhibitors 
(Complete Mini EDTA-free protease inhibitor tablets, 
1 tablet ⋅ 50 mL-1, Roche), 20 mM imidazole and 150 
mM NaCl for 1 h by rotation at 4 °C. The insoluble 
material was separated from the soluble fraction by 
centrifugation (200,000 g, 45 min, 4 °C). Nickel 
sepharose slurry (1 mL, corresponding to 0.7 mL 
resin; GE healthcare) was added to the soluble 
fraction; the mixture was stirred at 4 °C for 1 h. The 
nickel resin was harvested by centrifugation (100 g, 10 
min, 4 °C), transferred to a proteus 1-step batch midi 
spin column (Generon), and washed with 30 column 
volumes (CV) of buffer A (20 mM HEPES pH 7.0, 150 
mM NaCl, 40 mM imidazole, 0.2 mg ⋅ mL-1 tetraoleoyl 
cardiolipin / 0.2% (w/v) dodecyl maltose neopentyl 
glycol) (100 g, 10 min, 4 °C); followed by 10 CV of 
buffer B (20 mM HEPES pH 7.0, 50 mM NaCl, 0.2 mg ⋅ 
mL-1 tetraoleoyl cardiolipin / 0.2% (w/v) dodecyl 
maltose neopentyl glycol) (100 g, 7 min, 4 °C). The 
nickel resin was resuspended in buffer and incubated 
with 20 mM imidazole, 30 µg factor Xa protease and 5 
mM calcium chloride on a rotator at 4 °C overnight. 
The protein was eluted by centrifugation (500 g, 2 
min, 4 °C); the concentration of the purified protein 
was then measured by spectrometry (NanoDrop 
Technologies) at 280 nm (extinction coefficient: 47,120 
M-1 cm-1; protein mass: 33,019 Da). Imidazole and 
NaCl were removed using a midi PD-10 desalting 
column according to the manufacturer’s instructions 
(GE Healthcare) at 4 °C. 
Thermostability analysis of the hAAC1 carrier 
and drug interactions 
To determine protein stability and to screen 
drugs to identify potential hAAC1 inhibitors, the 
thiol-specific fluorescent probe N-[4-(7-diethylamino- 
4-methyl-3-coumarinyl)phenyl] maleimide (CPM) 
[67] and the Rotor-Gene-Q (Qiagen) were used, using 
a modified protocol [68]. CPM stocks (5 mg ⋅ mL-1 in 
DMSO) were diluted to 0.1 mg ⋅ mL-1 and equilibrated 
with purification buffer B for 10 min in the dark, 
before mixing with 3 µg of purified protein and 
compound. The mixture was equilibrated for a further 
10 min in the dark at 4 °C. As binding of inhibitors can 
be state-dependent (for example, CATR binds 
exclusively to the cytoplasmic-open state, and 
bongkrekic acid (BKA) binds exclusively to the 
matrix-open state), it was necessary to also add the 
substrate ADP (5 μM) to allow cycling between states. 
The fluorescent intensity was measured at 460 nm 
(excitation) and 510 nm (emission) from 25 ºC to 90 ºC 
with a ramp of 1 ºC every 15 s. Data analysis and 
determination of the apparent melting temperature of 
the protein (Tm) were carried out with the software 
provided with the instrument. 
Reconstitution of protein into liposomes 
A mix containing E. coli polar lipid extract 
(#100600P, Avanti Polar Lipids), egg 
L-α-phosphatidylcholine (#890704 (EPC-609), Avanti 
Polar Lipids) and tetraoleoyl cardiolipin (#840012C, 
Avanti Polar Lipids) in a 15:5:1 (w/w) ratio was dried 
under a stream of nitrogen. The lipid mixture was 





washed with methanol, and dried as before. Lipids 
were re-hydrated in 20 mM HEPES pH 7.0, 50 mM 
NaCl and, when required, ATP was added to a final 
concentration of 1 mM. The detergent pentaethylene 
glycol monodecyl ether (C10E5) was added to a final 
concentration of 1.6% (v/v) and the lipids were 
solubilized by vortexing and incubated on ice for one 
hour until the lipid emulsion became clear, 
subsequently, 30 μg protein was added per sample. 
The pentaethylene glycol monodecyl was removed by 
multiple additions of SM-2 bio-beads (Bio-Rad). Five 
additions of bio-beads were made to the master mix 
every 20 min with inversion at 4 °C: four of 60 mg, 
and the final of 480 mg. The samples were incubated 
overnight at 4 °C with inversion. Bio-beads were 
removed by passage of the sample through empty 
micro-bio spin columns (Bio-Rad). For exposed 
conditions, drugs were internalized at various 
concentrations (0.1, 0.3, 1, 3, 10, 30 and 100 μM; 
concentration used indicated in each figure) by 
freeze-thaw (three cycles), and sealed 
proteoliposomes formed by 21 passages through a 
0.4-μm filter (Millipore). The external substrate was 
removed and exchanged into buffer (20 mM HEPES, 
pH 7.0 and 50 mM NaCl) using a PD10 desalting 
column (GE Healthcare). When required, drugs were 
also added externally to the indicated concentration 
as described below. 
Transport assays of wild-type and mutant 
AACs 
Transport assays were performed using the 
Hamilton MicroLab Star robot (Hamilton Robotics 
Ltd). 100 μL of proteoliposomes were loaded into the 
wells of a MultiScreenHTS + HA 96-well filter plate 
(pore size 0.45-μm, mixed cellulose ester, Millipore 
(#MSHAN4B)). Uptake of radiolabeled [33P]-ATP 
(Hartmann Analytic) in the presence or absence of 10 
μM or 100 μM compound was initiated by the 
addition of 100 μL buffer containing 1 μM [33P]-ATP. 
Uptake was stopped after 0, 10, 20, 30, 45, 60, 150 s 
and 5, 7.5 and 10 min by filtration and washing with 3 
times 200 μL ice-cold buffer (20 mM HEPES, pH 7.0 
and 50 mM NaCl). Levels of radioactivity was 
measured by adding 200 μL MicroScint-20 (Perkin 
Elmer) and measured using a TopCount scintillation 
counter (Perkin Elmer). Uptake curves were fitted 
according to the one-phase association model or 
Michaelis-Menten and initial rates were determined 
from the linear part of the uptake curves. Transport 
measurements were also carried out in presence of 
different concentrations of the investigated drugs (0.1, 
0.3, 1, 3, 10, 30 and 100 μM), added both internally and 
externally. The percentage of transport activity was 
plotted against the corresponding log10 inhibitor 
concentration in order to determine IC50-values of the 
tested compounds, the inhibitor concentration that 
caused a 50% reduction of the maximum transport 
activity. 
Molecular surface and charge calculations 
2D structures of all compounds were drawn in 
MarvinSketch 20.15.0 (ChemAxon), and protonation 
was adjusted to pH 7.0. Next, 3D structures were 
generated using Avogadro 1.2.0 [69] and energy 
minimization was performed according to the 
MMFF94 protocol with a steepest descent algorithm 
and 10 steps per update. Van der Waals surfaces (0.18 
Å resolution), with electron density visualizations, 
were calculated using Avogadro’s surfaces plugin. 
Solvent accessible surfaces (hydrophobic, polar, 
positively charged and negatively charged) and 
partial charges were calculated using MarvinSketch. 
BKA and CATR structures were obtained from their 
respective crystal structures PDB: 6GCI and PDB: 
4C9G, published previously [29, 63]. 
Quantification and statistical analyses 
For CPM-based thermostability analysis, the 
apparent melting temperature (Tm) was calculated 
from the first derivative of the thermal denaturation 
profile. The average apparent Tm of ‘no addition’ 
control samples was subtracted from the apparent Tm 
measured for each compound addition in the same 
run, which provides the ΔTm. Statistical significance 
between groups was assessed by one-way ANOVA 
followed by Dunnett's post hoc analysis to correct for 
multiple comparisons test were performed using in 
Prism 8 (GraphPad Software, USA). Transport uptake 
curves (Figures 2F) were fitted with a one-phase 
association curve and dose-response curves (Figure 
4F-E) using a sigmoidal dose-response regression 
curve-fitting. All values are shown as mean ± SEM, 
unless indicated otherwise. 
Results 
Metabolic profiling of proposed AAC inhibitors 
indicates mitochondrial dysfunction and 
reduced ADP-dependent respiration 
Many previously reported AAC inhibitors have 
been associated with cellular and mitochondrial 
toxicity [43, 46, 48, 49, 55]. A systematic comparison of 
their metabolic effects has not been performed. We 
assessed the effects of direct exposure of eighteen 
previously reported and commercially-available AAC 
inhibitors on cellular respiration in human HeLa cells 
(Figure 1A). All compounds were tested at a 100  µM, 
as concentrations of at least 200-fold plasma Cmax 
demonstrated a more sensitive and specific prediction 
of the toxicity observed in humans [70]. The canonical 





AAC inhibitors bongkrekic acid (BKA) and 
carboxyatractyloside (CATR) were included, and a 
strong and immediate inhibition of routine respiration 
could be observed with BKA, which is membrane 
permeable, but not with CATR (Figure 1B). Of the 
eighteen compounds tested, only CD-437, equisetin, 
ethacrynic acid, ibipinabant and tretinoin significantly 
inhibited respiratory capacity (Figure 1C). Addition 
of the mitochondrial uncoupler FCCP, to induce 
maximal respiration, exacerbated the inhibitory effect 
of most of these drugs, but did not reveal other 
compounds with a direct inhibitory effect (Figure 
1D). Determination of the leak respiratory capacity 
(ADP-independent respiration; Figure 1E), enabled us 
to determine ADP-linked respiration, which was 
almost completely inhibited by BKA and CD-437 
(Figure 1F). In addition, equisetin, ethacrynic acid, 
ibipinabant, and tretinoin significantly decreased 
ADP-linked oxygen consumption. The significant 
increased leak respiration by tretinoin (Figure 1E), 
which is also observed with indomethacin, is 
indicative of an increased proton leakage over the 
mitochondrial inner membrane. Therefore, the 
observed decrease in ADP-linked respiration could 
have been induced by an effect on mitochondrial 
coupling rather than directly on ADP-linked 
respiration. 
To investigate whether any of the compounds 
may have been hindered by the plasma membrane, 
we permeabilized the cells (Figure 1A). Upon 
permeabilization, CATR completely inhibited 
ADP-driven respiration (Figure 1G). Moreover, 
permeabilization led to a significant respiratory 
inhibition by suramin and zidovudine (Figure 1H). 
Similar to the effects observed in intact cells (Figure 
1F), equisetin and ethacrynic acid inhibited 
ADP-driven respiration (Figure 1H). Remarkably, 
ibipinabant and CD-437 did not inhibit ADP-driven 
respiration in permeabilized cells, whereas they did in 
intact cells, indicating an indirect effect. 
The observed inhibition of respiration was 
shown to be a valuable measure of the cellular 
metabolic impact of the proposed AAC inhibitors. 
However, this remains a complex model system, 
illustrated by the mild inhibition of ADP-driven 
respiration in permeabilized cells. Therefore, further 
analysis is required to assess AAC interactions and 
inhibition directly. 
Functional expression and purification of 
human AAC1 in S. cerevisiae 
To provide a more unambiguous and accurate 
method to assess and compare drug-induced AAC 
inhibition, we adapted previously used methods to 
purify detergent-solubilized human AAC [29, 30, 63, 
68]. The isolation and expression of the properly 
folded monomeric four human AAC isoforms in 
bacteria and yeast cells is known to be problematic 
[59, 71, 72]. We codon-optimized the sequence and 
truncated the first 10 residues of human AAC1 
(hAAC1Δ1-10). The truncation does not interfere with 
substrate binding, or any other important functional 
elements of the carrier, but might lead to increased 
expression levels (Figure 2A and Figure S2) [29, 73].  
Carrier function was assessed by its capacity to 
complement non-fermentable growth of a double 
AAC deletant strain (WB.12, ∆AAC1, ∆AAC2) [73]. 
Complementation with full length human AAC1 
(hAAC1) could not rescue growth of the deletant 
strain (Figure 2B). Cellular growth could be recovered 
with the hAACΔ1-10, although not to the same extent 
as wild-type S. cerevisiae AAC2 (ScAAC2), 
demonstrating that the truncation variant was active 
as an ADP/ATP carrier. Subsequently, we optimized 
the protein purification, resulting a yield of ~1.3 mg 
protein per gram of mitochondria, which provides 
sufficient protein to probe interactions with AAC in 
thermostability and transport assays (Figure 2C). 
Next, we used thermostability analysis to 
evaluate protein stability. We monitored the 
unfolding of the protein population in a temperature 
ramp in the presence of the fluorescent dye 
N-[4-(7-diethylamino-4-methyl-3-coumarinyl)phenyl] 
maleimide (CPM), which binds to four cysteines 
buried inside the carrier that become solvent 
accessible upon protein unfolding. Consistent with 
previous thermostability analysis of ScAAC2 and 
TtAAC [34, 68], sigmoidal unfolding profiles were 
obtained for hAAC1Δ1-10 (Figure 2D). First-order 
derivatives showed a single peak, with an apparent 
melting temperature (Tm) of 47.0 ± 1 °C (Figure 2E), 
which represents the temperature at which 
approximately half of the population is unfolded. This 
value is similar to those observed for other AACs, 
such as ScAAC2 (44.7 °C) and TtAAC (49.5 °C) [68], 
which shows that the detergent-solubilized protein is 
folded and stable. Moreover, binding of canonical 
AAC inhibitors BKA and CATR lead to an increase in 
apparent melting temperature to 55 ± 1 °C and 80 ± 3 
°C respectively (Figure 2E), as observed for other 
orthologs [68]. 
We next reconstituted human AAC1 into 
proteoliposomes, which allowed us to measure 
transport activity directly. CATR- and 
BKA-inhibitable [33P]-ATP/ATP transport activity, in 
which internal unlabeled ATP was exchanged for 
external radiolabeled ATP, was observed, but no 
activity was seen in the control assay (Figure 2F-G). 
Finally, we determined an apparent Km of 3.2 μM 
(95%-confidence interval 2.1 – 4.2 μM) (Figure 2H).  







Figure 1 | Cellular metabolic profiling of proposed AAC inhibitors. (A) Effects of eighteen proposed AAC inhibitors on oxygen consumption rates (OCR) were 
investigated at 100  µM after 90 min exposure in intact and permeabilized cells. (B) For determination of cellular oxygen consumption rates, routine oxygen consumption was 
allowed to reach a stable signal (T0), which was used for normalization of all oxygen traces. Before normalization, non-mitochondrial respiration was determined after addition 
of rotenone (rot) and antimycin A (AA), and subtracted from all traces. Canonical AAC inhibitors bongkrekic acid (BKA, red circles and bars) and carboxyatractyloside (CATR, 
blue circles and bars) were used as positive controls. (C) Compounds were added and routine oxygen consumption was determined. NI: not interpretable, due to interference 
of the compounds with the fluorescent measurements. (D-E) The mitochondrial complex V inhibitor oligomycin (oligo) was added to determine leak respiration. Subsequent, 
addition of the mitochondrial membrane potential uncoupler FCCP resulted in maximal uncoupled respiration. (F) Subtraction of LEAK from ROUTINE respiratory rates 
resulted in ADP-linked respiratory rates. (G) To determine oxygen consumption in permeabilized cells, cells were permeabilized with digitonin in the presence of complex 
I-linked substrates glutamate and malate, just before initiation of each run, after which compounds were added and incubated for 90 min. (H) ADP was added to determine 
ADP-driven respiration, subtraction of non-mitochondrial respiration after addition of rot and AA was performed as described above. Statistical analysis: one-way ANOVA with 
Dunnett’s post hoc analysis to compare values to control *p<0.05; **p<0.01; ***p<0.001. Mean ± SEM; n=3 biologically independent experiments. 






Figure 2 | Expression and purification of human AAC1. (A) Model of the N-terminal truncated protein hAAC1Δ1-10 showing that important functional elements are not 
affected by removal of the first 10 amino acids. (B) Functional complementation tests were carried out using a ten-fold serial dilution series, plated on YPG (a non-fermentable 
carbon source), and incubated for 6 days at 30 °C. (C) Instant-blue stained SDS-PAGE gel of purified hAAC1Δ1-10. (D) Typical unfolding curves of 3 μg hAAC1Δ1-10 in the 
absence and presence of 10 μM BKA (red line) and 10 μM CATR (blue line). (E) The peak in the derivative of the unfolding curve (dF/dT) is the apparent melting temperature 
(Tm) (F) [33P]-ATP uptake curves of hAAC1Δ1-10 reconstituted into proteoliposomes loaded with or without 1 mM ATP in the absence or presence of 10 μM CATR (blue 
curve) or 10 μM BKA (red curve) (G) Initial transport rates, calculated from panel (F) (H) Kinetics of ATP uptake. The internal ATP concentration was 1 mM. The apparent Km 
was determined using the Michaelis-Menten function. Statistical analysis: one-way ANOVA with Dunnett’s post hoc analysis to compare values to control *p<0.05; **p<0.01; 
***p<0.001. Mean ± SD; n=4 biologically independent experiments. 
 
This apparent Km of transport is consistent with 
previously a published value using hAAC1 expressed 
and assayed in intact yeast mitochondria (KmADP 3.7 
μM) [58]. Moreover, it is in the same low micromolar 
range as the Km determined using hAAC fused to the 
periplastic maltose binding protein expressed in E. coli 
(KmATP 23.7 μM) [60], as the latter Km may be slightly 
higher due to interference of the periplastic maltose 
binding protein. Taken together, our work provides 
direct evidence that the reconstituted human AAC1 is 
stable, functional and displays the expected 
characteristics of the mitochondrial AAC. 
Drug-carrier interactions induce 
thermostability shifts of the human AAC1 
Ligands are recognized by transport proteins 
through specific interactions. The formation of these 
additional bonds leads to an increase in the total 
number of interactions, resulting in an overall 
increase in the stability of the ligand-bound species 
compared to the unliganded species. This can be 
detected as a change in the apparent melting 
temperature of a protein population [74]. We have 
shown that inhibitors of transport proteins cause an 
increase in protein thermostability [68, 74, 75]. 





Furthermore, we have used thermostability shift 
analyses to identify substrates of a range of different 
transport proteins using this same principle [74]. 
Compared to transport assays, thermostability 
analyses are high-throughput and relatively 
inexpensive. 
We evaluated 18 commonly used drugs and 
experimental compounds previously reported to 
inhibit AAC. As expected, the addition of both CATR 
(∆Tm; 35.8 ± 3.4 °C) and BKA (∆Tm; 11.7 ± 0.9 °C) 
resulted in a large increase in protein stability relative 
to no-inhibitor control assays (Figure 3A). 
Remarkably, none of the previously reported AAC 
inhibitors resulted in a statistically significant change 
in thermal stability at 10 μM (Figure 3A). However, at 
100 μM, suramin stabilized the carrier significantly by 
4.3 ± 1.1 °C (Figure 3B and 3C). In addition, thermal 
shift screening experiments usually produce 
destabilizing hits (negative ∆Tm) as well as stabilizing 
hits (positive ∆Tm). Here we observed that sertraline 
(∆Tm; 5.7 ± 1.9 °C) and leelamine (∆Tm; 4.5 ± 1.8 °C) 
destabilize AAC (Figure 3D-E). In the presence of 1 
mM CD-437 a statistically significant destabilization 
was also observed (Figure S1). Although this method 
could benefit from using increasing concentrations of 
the compounds, it is not always possible due to 
quenching of the fluorescent signal. 
 
 
Figure 3 | Drug-carrier interactions induce specific thermostability shifts of the human AAC1. (A) The difference in melting temperature (ΔTm) is calculated by 
subtraction of the apparent melting temperature in the absence of compound from the one in its presence. The effect on stability of all compounds was determined at (A) 10 and 
(B) 100 μM in the presence of 5 μM ADP. Individual melting curves (upper panels) and first order derivatives (lower panels) of (C) suramin, (D) leelamine, (E) sertraline, which 
significantly altered the thermostability of the hAAC1Δ1-10. No addition (black trace), 10 μM compound (dark blue trace), 100 μM compound (light blue trace). Statistical 
analysis: one-way ANOVA with Dunnett’s post hoc analysis to compare values to control *p<0.05; **p<0.01; ***p<0.001. Mean ± SEM; n=3 biologically independent experiments. 






Figure 4 | Drug-induced inhibition of AAC-mediated ATP transport. The effect of proposed AAC inhibitors on [33P]-ATP uptake was monitored in proteoliposomes. 
Compounds were tested at (A) 10 or (B) 100 μM and were present internally and externally in the assay. Data are expressed as percentage inhibition, where 100% inhibition 
represents inhibition by CATR (blue). NI: not interpretable, due to extreme variability of the observed effects, as both inhibition and stimulation could be detected, even with six 
replicates. (C-E) IC50 values were calculated for (C) suramin, (D) chebulinic acid, and (E) CD-437. Statistical analysis: one-way ANOVA with Dunnett’s post hoc analysis to 
compare values to control *p<0.05; **p<0.01; ***p<0.001. Mean ± SEM; n = 6 biologically independent experiments. 
 
Thermostability shift assays can be used as an 
effective high-throughput method to limit the number 
of potential off-target candidates from large 
compound libraries, providing important insights 
about transporter-drug interactions. 
Drug-induced inhibition of AAC-mediated 
ATP transport  
Next, we reconstituted human AAC1 into 
proteoliposomes to investigate the inhibitory effects 
of the proposed inhibitors directly. As expected, 
CATR and BKA fully inhibited AAC-mediated ATP 
transport at both 10 μM and 100 μM (Figure 4A-B). At 
10 μM only suramin (92 ± 3%), chebulinic acid (83 ± 
2%) and CD-437 (37 ± 2%) showed 
statistically-significant inhibition of ATP transport, 
relative to the inhibition observed with CATR 
(defined as 100%) (Figure 4A). Of note, leelamine and 
sertraline showed exceptional variability in transport 
rates (both stimulation and inhibition), which did not 
allow us to plot these rates with confidence. In 
addition to suramin, chebulinic acid and CD-437, 
furosemide and leelamine showed complete 
inhibition of ATP transport at 100 μM (Figure 4B). 
Statistically significant inhibition was also observed 
with anthralin (77 ± 7%), indomethacin (44 ± 5%), 
sertraline (34 ± 5%) and tretinoin (59 ± 5%). Finally, 
we determined IC50-values for the three most potent 
inhibitors. For suramin (2.4 μM; 95%-confidence 
interval, 0.8 - 7.5 μM) and chebulinic acid (6.5 μM; 
95%-confidence interval, 2.4 - 17 μM) their inhibitory 
potential is comparable to previously observed 
IC50-values in hAAC2 (2.1 and 0.3 µM) [55]. The 
inhibitory potential observed for CD-437 (20 μM; 
95%-confidence interval, 2.6 - 162 μM) (Figure 4C-E) is 
also comparable to previously observed IC50-values 
for all human AAC isoforms expressed in yeast (9.5 - 
22 µM) [49].  






Figure 5 | Molecular surface charge distribution are shared inhibitor and substrate characteristics. (A-B) The electrostatic potential surface is shown for the AAC 
binding pocket. (A) The cytosolic-state model is based on the CATR-inhibited ScAAC2 structure (PBB: 4C9G) [63] and (B) the matrix-state on the BKA-inhibited TtAAC 
structure (PDB: 6GCI) [29]. Surface is colored by electrostatic potential (blue, +20 kT e-1; white, neutral; red, -20 kT e-1). Surface charge distributions are shown for the AAC 
substrates (C) ADP and (D) ATP, the canonical AAC inhibitors (E) CATR and (F) BKA, as well as other AAC inhibitors (G) CD-437, (H) suramin and (I) chebulinic acid. 
Surface is colored by electrostatic potential (blue, +15 kT e-1; white, neutral; red, -15 kT e-1). Molecular surface calculations were performed at pH 7.0 for all substrates and 
inhibitors, and included the (J) formal charge and (K) negative charged solvent accessible area. Compounds were classified either as strong inhibitors (inhibition at 10 and 100 
µM, Figure 4A-B), weak inhibitors (only inhibition at 100 µM, Figure 4B) or non-binders. Substrates are ADP and ATP. Statistical analysis: one-way ANOVA with Bonferroni’s 
post hoc analysis to compare all conditions *p<0.05; **p<0.01. Data presented as Box-Whisker plots. 





Molecular surface charge and hydrophobicity 
are shared and important inhibitor 
characteristics 
These analyses also allow us to identify which 
physicochemical properties of a compound are 
important for AAC inhibition. Previous observations 
have shown that almost all regions of the carrier are 
embedded in the inner membrane, which leaves 
nearly no exposed surfaces other than the central 
cavity [29, 63]. Thus, this is the most likely site of 
binding for compounds. Moreover, the largely 
positively charged binding pocket is primed to bind 
the negatively-charged substrates ADP and ATP [29] 
(Figure 5A-D). Consistent with this, both canonical 
AAC inhibitors BKA and CATR are negatively 
charged, with formal charges of -3 and -4, respectively 
(Figure 5E-F). A similar charge distribution could be 
observed with the strong AAC inhibitors suramin and 
CD-437 (Figure 5G-H), which may suggest a similar 
mode of interaction. A more heterogeneous 
distribution of negative charges could be observed 
with the inhibitor chebulinic acid (Figure 5I). To 
quantify the relevance of this negatively charged area 
for AAC inhibitors further, we categorized them as 
non-binders, weak inhibitors (only inhibition at 100 
µM, Figure 4B) or strong inhibitors (inhibition at 10 
and 100 µM, Figure 4A-B). Compounds that did not 
or only weakly inhibit AAC have significantly less 
negative charge, whereas the formal charge of strong 
inhibitors is similar to that of the substrates ADP and 
ATP (Figure 5J). To investigate whether these 
negative charges are all solvent exposed, which is an 
important property for their interaction with AAC, we 
calculated the negatively charged solvent exposed 
surface area. This area was significantly larger in 
strong inhibitors compared to compounds that did 
not or only weakly inhibit AAC (Figure 5K). 
Collectively, this suggests that potent AAC inhibitors 
consist of a negatively charged region and a 
hydrophobic region, as observed in the substrates 
ADP and ATP. 
Discussion 
A steadily increasing number of commonly 
prescribed drugs are known to interfere with 
mitochondrial function, but the underlying molecular 
mechanisms are largely unknown. Mitochondrial 
transport proteins form a significant class of potential 
mitochondrial off-targets, but are seldom considered. 
So far, most drug interactions with these transport 
proteins have been reported for mitochondrial AAC, 
but they have never been validated. Here, we describe 
the purification and functional reconstitution of 
hAAC1, which provides a direct tool to study 
drug-carrier interactions. We have used 
thermostability assays to investigate binding of 
hAAC1 for a subset of high affinity inhibitors, and 
inhibition kinetics using transport assays with hAAC1 
reconstituted in proteoliposomes, which identified a 
wider range of inhibitors. Collectively, chebulinic 
acid, CD-437 and suramin were identified as the most 
potent inhibitors of AAC, with IC50-values in the low 
micromolar range. Therefore, these compounds 
showed a comparable inhibitory potency compared to 
BKA (2.0 µM) [55], but still far less potent compared to 
CATR for which IC50-values are in the low-nanomolar 
range [76]. Combined with the inhibitory effects of 
suramin on respiratory capacity in intact cells, this 
agrees with the many adverse drug effects observed 
with suramin, including adrenal insufficiency, anemia 
and peripheral neuropathy [77]. Another six 
compounds inhibited at 100 µM, but at this 
concentration, they are unlikely to be physiologically 
relevant. Finally, we showed that the presence of a 
negatively charged surface area associates with 
inhibitor strength. Remarkably, half of all previously 
published AAC inhibitors do not show significant 
inhibition in our assays, even at 100 µM, so they were 
false positives or exert their action on mitochondrial 
respiration via indirect effects. 
The results obtained for suramin and chebulinic 
acid are consistent with previously reported data, 
obtained using hAAC2 expressed in inclusion bodies, 
refolded and reconstituted into proteoliposomes [55]. 
CD-437 was shown to inhibit ADP uptake in isolated 
yeast mitochondria and L. lactis overexpressing all 
four human isoforms [49]. CD-437 is a retinoid, which 
may point at a compound class inhibitory effect, as 
AAC inhibition was also observed with the prototypic 
retinoid tretinoin [44]. Notably, leelamine 
demonstrated variable effects on transport, which is 
in agreement with the high variability at a 10 μM 
concentration in this study [49]. It is important to note 
that many of the compounds that showed no 
inhibition in this study were previously proposed to 
inhibit AAC based on measurements of ADP/ATP 
exchange in intact bovine or rat mitochondria [39-45, 
47, 48, 54]. All these methods rely on functional 
oxidative phosphorylation, as well as other central 
metabolic pathways to drive ADP/ATP exchange. 
These drugs may inhibit these other systems, leading 
indirectly to decreased ADP and ATP transport rates. 
This notion is also supported by our assessment of the 
respiratory capacity, which demonstrates that both 
equisetin and ethacrynic acid are significant inhibitors 
of all respiratory states assessed, but they did not 
inhibit AAC-mediated ATP transport. These false 
positives illustrate the importance of using direct 
experimental systems. Importantly, respiratory 





capacity, especially ADP-linked and ADP-dependent 
oxygen consumption rates, was not affected by all 
AAC inhibitors, as chebulinic acid, furosemide and 
indomethacin did not inhibit either. For chebulinic 
acid this could potentially be explained by a poor 
mitochondrial uptake, due to high hydrophilicity. 
Overall, assessment of the cellular respiratory 
capacity does not seem to provide a valid measure of 
the capacity of a drug to inhibit AAC, but offers a 
method to evaluate the effects of these compounds on 
cellular metabolism as a whole. 
In line with enhanced thermostability with the 
canonical AAC inhibitors BKA and CATR, which 
have also been observed previously [29, 34, 68], 
suramin increased AAC stability. In addition, the 
observed dose-dependent increase of stability with 
suramin correlated with transport inhibition (Figure 
3A-B; Figure 4A-B). Even though hAAC inhibited 
with both leelamine and sertraline displayed 
decreased thermostability, they did inhibit 
AAC-mediated ATP transport, showing that both 
stabilizers and destabilizers need to be considered. 
None of the other compounds that inhibited transport 
at high concentrations, such as anthralin, chebulinic 
acid, furosemide, indomethacin, and tretinoin, caused 
a significant shift in thermostability. Although there 
might some technical issues, e.g. interference with the 
fluorescent signal with chebulinic acid, these data 
may indicate that they are not strong binders. 
Similarly, the difference in thermal shifts observed 
between suramin and BKA, which have comparable 
IC50-values (2.4 and 2.0 µM) in transport assays, 
shows that these assays probe fundamentally 
different properties of the protein in relation to the 
binding of these compounds. The former tests the 
number and strength of interactions at high 
temperatures, when the carrier is resuspended in 
detergent solution, whereas the latter tests the effect 
of the compound on the transport cycle at room 
temperature, when the carrier is incorporated in the 
membrane. At 1 mM we observed a destabilization 
effect with CD-437 (Figure S1), which supports the 
idea that higher concentrations are needed to see an 
effect on protein thermostability relative to the 
concentrations needed to observe inhibition in 
transport assays. Transport assays using reconstituted 
AAC provide the most straightforward and sensitive 
experimental approach to evaluate and compare 
drug-induced inhibition, even though they are 
low-throughput and expensive compared to 
thermostability assays, which provide a more 
practical and fast approach to identify strongly 
binding AAC inhibitors from libraries of compounds. 
It is important to note that the most potent inhibitor of 
AAC-mediated ATP transport, suramin, also induced 
stabilization of hAAC in our thermostability shift 
assays. 
Previously, comparison of the different human 
AAC isoforms demonstrated only minor differences 
in IC50-values, including for CD-437 and leelamine 
[49]. This observation can be explained by the 
conserved sequence homology and structural 
similarities of these different isoforms, which all share 
the three contact points of the substrate binding site 
[78], and many other functionally important features, 
such as the matrix salt bridge network [33, 63], 
cytoplasmic salt bridge network [29, 34, 63, 78], the 
glutamine braces [63], tyrosine braces [29], and motifs 
involving small amino acid residues [1, 29, 31] (Figure 
S2). Consequently, compounds that inhibited hAAC1 
in our study can also be expected to inhibit the other 
human AAC isoforms. This idea is emphasized by the 
comparable inhibitory potency (IC50-values) we 
observed for chebulinic acid and suramin in hAAC1 
(6.0 and 2.4 µM) with those previously observed in 
hAAC2 (2.1 and 0.3 µM) [55]. 
In conclusion, we have provided initial 
characterization of the human AAC1 and 
demonstrated its relevance to study drug-induced 
inhibition. Moreover, the ability to compare 
compounds within the same experimental system, 
including transport assays using reconstituted, 
detergent-purified protein, enabled us to gain new 
insights into the chemical compound features 
important for inhibition. Many other mitochondrial 
transport proteins are off-targets for commonly 
prescribed drugs, such as the mitochondrial pyruvate 
carrier, which is inhibited by thiazolidinediones [79, 
80] and the mitochondrial dicarboxylate carrier, 
which is inhibited by cephalosporin antibiotics [81]. 
Therefore, transport proteins can play a pivotal role in 
drug-induced mitochondrial dysfunction. Conse-
quently, similar experimental approaches are also 
warranted for these and other mitochondrial 
transport proteins. Eventually, these analyses will 
provide insights in the role of mitochondrial transport 
proteins in drug-induced mitochondrial dysfunction 
and will thereby contribute to the development of 
drugs with an enhanced safety profile. 
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